GlassScriptPhysician profile
Brittany A Sullivan
NPI 1063859452
$1,970.85
in general payments reported to CMS, 2019-2025
29 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $177 · 2020: $260 · 2021: $366 · 2022: $294 · 2023: $429 · 2024: $197 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $873.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $873.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $685.62 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Pfizer INC. | $130.13 | 2019-2025 | |
| Glaxosmithkline, LLC. | $115.54 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Lilly USA, LLC | $87.16 | 2019-2021 | |
| Novo Nordisk INC | $86.66 | 2021-2025 | Wegovy, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.86 | 2021-2025 | Jardiance |
| Amarin Pharma, INC. | $77.16 | 2020-2021 | |
| Amgen INC. | $68.76 | 2020-2024 | Otezla, Repatha |
| Takeda Pharmaceuticals U.S.A., INC. | $66.70 | 2021-2022 | |
| Allergan, INC. | $65.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $65.14 | 2019-2020 | |
| Astellas Pharma US INC | $56.03 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $52.62 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $44.04 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $42.26 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $34.77 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $26.90 | 2020-2021 | |
| Eisai INC. | $21.87 | 2025 | |
| Exact Sciences Corporation | $20.47 | 2025 | Cologuard Collection Kit |
| Inspire Medical Systems, INC. | $18.43 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $17.09 | 2024 | Gvoke Hypopen |
| Abbott Laboratories | $16.80 | 2023 | Freestyle Libre 2 |
| Shield Therapeutics INC | $15.74 | 2023 | Accrufer |
| Currax Pharmaceuticals LLC | $13.76 | 2023 | Nexletol, Nexlizet, Contrave |
| Vbi Vaccine (Delaware) INC. | $13.20 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $13.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.16 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.43 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Sullivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.